Pharmacyclics’ Imbruvica Extends Survival in Elderly Leukemia PatientsTheStreet.comCHICAGO (TheStreet) — Pharmacyclics (PCYC) and Johnson & Johnson’s (JNJ) blood-cancer drug Imbruvica reduced the risk of dying by 57% compared to GlaxoSmithKline’s (GSK) Arzerra when used to treat elderly patients with relapsed chronic …Ibrutinib (IMBRUVICA®) RESONATE™ Data Show Significant Improvements in …MarketWatchPhase 3 study strengthens support of ibrutinib as second-line therapy for CLLEurekAlert (press release)all 5 news articles …Read Full Story
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients - TheStreet.com
Real Estate of Cebu
